Arcus Biosciences Quarterly Income Statement
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcus Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Arcus Biosciences generated $41.0 million in revenue, down 74.4% from the same quarter a year earlier. Arcus Biosciences reported a net loss of $91.0 million, compared with net income of $0 a year earlier. Operating margin was -234.1%.
Diluted earnings per share came in at -$0.72.
Summary generated from market data by MetaCap's automated system. Methodology
Arcus Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.00M | 17.00M | 33.00M | 26.00M | 160.00M | 28.00M | 26.00M | 48.00M | 39.00M | 145.00M | -49.00M | 32.00M |
| Revenue growth (YoY) | -74.38% | -39.29% | +26.92% | -45.83% | +310.26% | -80.69% | — | +50.00% | +34.48% | +480.00% | — | -3.03% |
| Operating Expenses | 137.00M | 151.00M | 147.00M | 168.00M | 168.00M | 150.00M | 129.00M | 153.00M | 145.00M | 161.00M | 122.00M | 112.00M |
| Research & Development | 113.00M | 122.00M | 121.00M | 141.00M | 139.00M | 122.00M | 101.00M | 123.00M | 115.00M | 109.00M | 93.00M | 82.00M |
| Operating Income | -96.00M | -134.00M | -114.00M | -142.00M | -8.00M | -122.00M | -103.00M | -105.00M | -106.00M | -16.00M | -91.00M | -80.00M |
| Interest Expense | 3.00M | 3.00M | 2.00M | 3.00M | 2.00M | 1.00M | 2.00M | 1.00M | 0 | 1.00M | 0 | 1.00M |
| Other Income (Expense) | 5.00M | 6.00M | 8.00M | 7.00M | 8.00M | 10.00M | 10.00M | 13.00M | 13.00M | 12.00M | 11.00M | 11.00M |
| Pretax Income | -91.00M | -128.00M | -106.00M | -135.00M | 0 | -112.00M | -93.00M | -92.00M | -93.00M | -4.00M | -80.00M | -69.00M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1.00M | 0 | 0 | 0 | 1.00M | 2.00M |
| Net Income | -91.00M | -128.00M | -106.00M | -135.00M | 0 | -112.00M | -94.00M | -92.00M | -93.00M | -4.00M | -81.00M | -71.00M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.72 | -1.02 | -0.88 | -1.27 | 0.00 | -1.14 | -1.07 | -1.00 | -1.02 | -0.05 | -1.08 | -0.94 |
| EPS (Diluted) | -0.72 | -1.02 | -0.88 | -1.27 | 0.00 | -1.14 | -1.07 | -1.00 | -1.02 | -0.05 | -1.08 | -0.94 |
| Shares Outstanding (Basic) | 126.10M | 125.40M | — | 106.50M | 106.10M | 98.40M | — | 91.40M | 91.10M | 86.20M | — | 74.60M |
| Shares Outstanding (Diluted) | 126.10M | 125.40M | — | 106.50M | 106.50M | 98.40M | — | 91.40M | 91.10M | 86.20M | — | 74.60M |
| EBITDA | -93.00M | -132.00M | -111.00M | -140.00M | -6.00M | -119.00M | -100.00M | -103.00M | -104.00M | -13.00M | -88.00M | -79.00M |
| Operating Margin | -234.15% | -788.24% | -345.45% | -546.15% | -5.00% | -435.71% | -396.15% | -218.75% | -271.79% | -11.03% | 185.71% | -250.00% |
| Net Margin | -221.95% | -752.94% | -321.21% | -519.23% | 0.00% | -400.00% | -361.54% | -191.67% | -238.46% | -2.76% | 165.31% | -221.87% |
This table shows 12 quarterly periods of Arcus Biosciences's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow RCUS's reporting calendar. What is a income statement?